세계의 체외 폐 모델 시장 : 시장 규모, 예측, 점유율, 동향, 성장기회 분석 보고서 - 유형별, 용도별, 최종 사용자별, 지역별(2021-2031년)

The In Vitro lung models market size is projected to reach US$ 1,530.11 million by 2031 from US$ 446.35 million in 2024. The market is estimated to register a CAGR of 19.4% during 2025-2031. Major factors driving the market growth include a surging prevalence of respiratory diseases and the rising adoption of in vitro models as an alternative to animal testing. Further, Applications of 3D cultures and AI in oncology is likely to boost the market during the forecast period. However, lack of skilled professionals are among the market deterrents.

According to a report published by the Global Initiative on Chronic Obstructive Lung Disease, ~65 million people suffer from obstructive pulmonary disease (COPD), and nearly 3 million people die from the disease each year, making it the fourth leading cause of mortality worldwide. According to the 2023 American Lung Association data, ~34 million Americans were affected by chronic lung diseases such as asthma and COPD. In 2022, ~11.7 million adults, or 4.6% of the population in the US, were diagnosed with COPD. As per an article published in the European Respiratory Journal in 2020, 36.58 million Europeans were reported to have COPD, which is projected to reach 49.45 million by 2050, representing a 35.2% relative increase. With the growing prevalence of smoking in developing countries and the aging population in high-income countries, the COPD prevalence is projected to rise over the next forty years. As per the World Health Organization (WHO) estimates, COPD will become one of the leading causes of death worldwide by 2030, and it is estimated that by 2060, there will be more than 5.4 million deaths yearly due to COPD and related conditions.

Therefore, respiratory diseases is spurring the demand for advanced research models to understand disease mechanisms and develop effective treatments.

In vitro lung models, such as precision-cut lung slices (PCLS), allow the study of airway constriction and inflammation, facilitating the evaluation of novel therapeutic targets for asthma and other respiratory conditions. Lung-on-a-chip devices have been developed to replicate the physiological conditions of the human lung. The University of Michigan's "lung-on-a-chip" device uses human lung-tissue cells cultured on a plastic chip with microscopic channels to simulate the conditions inside the lungs, providing new insights into diseases. Thus, the increasing demand for effective treatments and research models fuels the growth of the in vitro lung model market.

Moreover, two-dimensional (2D) cell cultures, or monolayers, are widely used in cellular biology to study diseases and for drug screening due to their cost-effectiveness, high throughput, easy replication, and results interpretation. However, they fall short in replicating the complex network of dynamic interactions present in the three-dimensional tumor microenvironment (TME) of living patient tumors. This aspect limits their ability to model cancer behavior and drug responses, as well as to isolate and maintain cancer cell lines from patient biopsies in 2D cultures. Traditional 2D cell cultures, while foundational, fall short in replicating the intricate TME and cellular interactions that characterize lung cancers in vivo. As cancer research advances, an increasing number of animals are being utilized in the creation of animal models. These animals include mice, rats, and other similar species. However, animal models exhibit low success rates in translating preclinical findings into effective clinical treatments; this has raised concerns about their reliability as predictors of human responses. To address these limitations, research is shifting toward more physiologically relevant human in vitro models (3D cell culture models)-such as spheroids, organoids, tumoroids, and microfluidic systems-that better mimic the TME, gene expression, and drug responses observed clinically. These models are critical for validating drug efficacy and improving preclinical testing, especially in lung cancer research. Integrating 3D models in drug screening is essential to validate findings from 2D cultures and assess the effects of anticancer drugs. Such approaches have proven to be fruitful for cancer drug screening and are emerging as a pivotal tool in shaping the future of lung cancer research and therapeutic development. The use of 3D cell culture models in lung cancer pharmacology research represents a paradigm shift in the approach toward understanding and treating lung diseases.

The comparative company analysis evaluates and categorizes the in vitro lung models market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global in vitro lung models market. The key market players are MatTek Corp, Lonza Group AG, Emulate, Inc, CN Bio Innovations Ltd, PromoCell GmbH, Charles River Laboratories International Inc, MIMETAS BV, InSphero AG, Organovo Holdings Inc, Draper, Inc, Epithelix, AlveoliX AG, and American Type Culture Collection (ATCC).

Based on type, the market is divided into 3D Models and 2D Models. The 3D Models segment held the largest In Vitro Lung Model Market share in 2024, and it is expected to register the highest CAGR during 2024-2031.

3D lung models replicate the complex architecture and cellular interactions of human lung tissue accurately. The enhanced physiological relevance makes them invaluable for drug discovery, toxicity testing, and disease modeling. The primary types of 3D lung models include spheroids, organoids, and precision-cut lung slices (PCLS). In 3D models, cells are cultured within a three-dimensional structure, offering advantages over traditional 2D models. These models closely replicate the architecture and microenvironment of the lung, enabling accurate simulation of physiological conditions. As a result, drug and therapeutic studies using 3D models tend to yield more accurate and reliable results than those derived from 2D models or animal models.

By application, In Vitro Lung Model market is segmented into drug discovery and toxicology studies, physiological research, regenerative medicine, and others. The drug discovery and toxicology studies segment held the largest share of the in vitro lung model market in 2024.

Per end user, In Vitro Lung Model market is segmented into pharmaceutical and biotechnology companies, academic and research institutes, and others. The pharmaceutical and biotechnology companies segment held the largest share of the In Vitro lung model market in 2024.

Various organic and inorganic strategies are adopted by companies operating in the in vitro lung models market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the in vitro lung models market are listed below.

In September 2024, MatTek Life Sciences, a biotech company specializing in the development of in vitro human tissues, announced the licensing of its organotypic human tissues to CellEx, a life science laboratory based in China. This strategic collaboration marks a milestone in the advancement and utilization of human tissues for research, pharmaceutical development, and safety assessment applications.

In June 2023, Emulate, Inc., a provider of next-generation in vitro models, announced the launch of the Emulate Chip-A1 Accessible Chip through an early access program. This new Organ-Chip design expands on the original Chip-S1-which models tissue-vascular interfaces with relevant biomechanical forces such as stretch and flow-by allowing users to create thicker tissues within the epithelial culture chamber and apply additional drug treatment options, including topical or aerosolized applications.

Table Of Contents

1. Introduction

• 1.1 Report Guidance
• 1.2 Market Segmentation

2. Executive Summary

• 2.1 Analyst Market Outlook

3. Research Methodology

• 3.1 Secondary Research
• 3.2 Primary Research
  • 3.2.1 Hypothesis formulation:
  • 3.2.2 Macro-economic factor analysis:
  • 3.2.3 Developing base number:
  • 3.2.4 Data Triangulation:
  • 3.2.5 Country level data:
• 3.3 Assumptions and Limitations

4. In-Vitro Lung Model Market Landscape

• 4.1 Overview
• 4.2 PEST Analysis
• 4.3 Regulatory Scenario

5. In-Vitro Lung Model Market - Key Market Dynamics

• 5.1 In-Vitro Lung Model Market - Key Market Dynamics
• 5.2 Market Drivers
  • 5.2.1 Surging Prevalence of Respiratory Diseases
  • 5.2.2 Rising Adoption of In Vitro Models as an Alternative to Animal Testing
• 5.3 Market Restraints
  • 5.3.1 Lack of Skilled Professionals
• 5.4 Market Opportunities
  • 5.4.1 Surging Funding and Investments for In Vitro Models
• 5.5 Future Trends
  • 5.5.1 Application of 3D Cultures and AI in Oncology
• 5.6 Impact of Drivers and Restraints:

6. In-Vitro Lung Model Market - Global Market Analysis

• 6.1 In-Vitro Lung Model Market Revenue (US$ Million), 2021-2031
• 6.2 In-Vitro Lung Model Market Forecast Analysis

7. In-Vitro Lung Model Market Analysis - by Type

• 7.1 3D Model
  • 7.1.1 Overview
  • 7.1.2 3D Model: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
• 7.2 2D Model
  • 7.2.1 Overview
  • 7.2.2 2D Model: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)

8. In-Vitro Lung Model Market Analysis - by Application

• 8.1 Drug Discovery and Toxicology Studies
  • 8.1.1 Overview
  • 8.1.2 Drug Discovery and Toxicology Studies: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
• 8.2 Physiological Research
  • 8.2.1 Overview
  • 8.2.2 Physiological Research: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
• 8.3 Regenerative Medicine
  • 8.3.1 Overview
  • 8.3.2 Regenerative Medicine: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
• 8.4 Others
  • 8.4.1 Overview
  • 8.4.2 Others: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)

9. In-Vitro Lung Model Market Analysis - by End User

• 9.1 Pharmaceutical and Biotechnology Companies
  • 9.1.1 Overview
  • 9.1.2 Pharmaceutical and Biotechnology Companies: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
• 9.2 Academic and Research Institutes
  • 9.2.1 Overview
  • 9.2.2 Academic and Research Institutes: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)
• 9.3 Others
  • 9.3.1 Overview
  • 9.3.2 Others: In-Vitro Lung Model Market - Revenue and Forecast to 2031 (US$ Million)

10. In-Vitro Lung Model Market - Geographical Analysis

• 10.1 Overview
• 10.2 North America
  • 10.2.1 North America In-Vitro Lung Model Market Overview
  • 10.2.2 North America: In-Vitro Lung Model Market - Revenue, 2021-2031 (US$ Million)
  • 10.2.3 North America: In-Vitro Lung Model Market Breakdown, by Type
    • 10.2.3.1 North America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Type
  • 10.2.4 North America: In-Vitro Lung Model Market Breakdown, by Application
    • 10.2.4.1 North America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Application
  • 10.2.5 North America: In-Vitro Lung Model Market Breakdown, by End User
    • 10.2.5.1 North America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by End User
  • 10.2.6 North America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
    • 10.2.6.1 North America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
    • 10.2.6.2 United States: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.2.6.2.1 United States: In-Vitro Lung Model Market Breakdown, by Type
      • 10.2.6.2.2 United States: In-Vitro Lung Model Market Breakdown, by Application
      • 10.2.6.2.3 United States: In-Vitro Lung Model Market Breakdown, by End User
    • 10.2.6.3 Canada: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.2.6.3.1 Canada: In-Vitro Lung Model Market Breakdown, by Type
      • 10.2.6.3.2 Canada: In-Vitro Lung Model Market Breakdown, by Application
    • 10.2.6.4 Mexico: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.2.6.4.1 Mexico: In-Vitro Lung Model Market Breakdown, by Type
      • 10.2.6.4.2 Mexico: In-Vitro Lung Model Market Breakdown, by Application
      • 10.2.6.4.3 Mexico: In-Vitro Lung Model Market Breakdown, by End User
• 10.3 Europe
  • 10.3.1 Europe In-Vitro Lung Model Market Overview
  • 10.3.2 Europe: In-Vitro Lung Model Market - Revenue, 2021-2031 (US$ Million)
  • 10.3.3 Europe: In-Vitro Lung Model Market Breakdown, by Type
    • 10.3.3.1 Europe: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Type
  • 10.3.4 Europe: In-Vitro Lung Model Market Breakdown, by Application
    • 10.3.4.1 Europe: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Application
  • 10.3.5 Europe: In-Vitro Lung Model Market Breakdown, by End User
    • 10.3.5.1 Europe: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by End User
  • 10.3.6 Europe: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
    • 10.3.6.1 Europe: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
    • 10.3.6.2 Germany: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.3.6.2.1 Germany: In-Vitro Lung Model Market Breakdown, by Type
      • 10.3.6.2.2 Germany: In-Vitro Lung Model Market Breakdown, by Application
      • 10.3.6.2.3 Germany: In-Vitro Lung Model Market Breakdown, by End User
    • 10.3.6.3 France: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.3.6.3.1 France: In-Vitro Lung Model Market Breakdown, by Type
      • 10.3.6.3.2 France: In-Vitro Lung Model Market Breakdown, by Application
      • 10.3.6.3.3 France: In-Vitro Lung Model Market Breakdown, by End User
    • 10.3.6.4 United Kingdom: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.3.6.4.1 United Kingdom: In-Vitro Lung Model Market Breakdown, by Type
      • 10.3.6.4.2 United Kingdom: In-Vitro Lung Model Market Breakdown, by Application
      • 10.3.6.4.3 United Kingdom: In-Vitro Lung Model Market Breakdown, by End User
    • 10.3.6.5 Italy: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.3.6.5.1 Italy: In-Vitro Lung Model Market Breakdown, by Type
      • 10.3.6.5.2 Italy: In-Vitro Lung Model Market Breakdown, by Application
      • 10.3.6.5.3 Italy: In-Vitro Lung Model Market Breakdown, by End User
    • 10.3.6.6 Spain: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.3.6.6.1 Spain: In-Vitro Lung Model Market Breakdown, by Type
      • 10.3.6.6.2 Spain: In-Vitro Lung Model Market Breakdown, by Application
      • 10.3.6.6.3 Spain: In-Vitro Lung Model Market Breakdown, by End User
    • 10.3.6.7 Rest of Europe: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.3.6.7.1 Rest of Europe: In-Vitro Lung Model Market Breakdown, by Type
      • 10.3.6.7.2 Rest of Europe: In-Vitro Lung Model Market Breakdown, by Application
      • 10.3.6.7.3 Rest of Europe: In-Vitro Lung Model Market Breakdown, by End User
• 10.4 Asia Pacific
  • 10.4.1 Asia Pacific In-Vitro Lung Model Market Overview
  • 10.4.2 Asia Pacific: In-Vitro Lung Model Market - Revenue, 2021-2031 (US$ Million)
  • 10.4.3 Asia Pacific: In-Vitro Lung Model Market Breakdown, by Type
    • 10.4.3.1 Asia Pacific: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Type
  • 10.4.4 Asia Pacific: In-Vitro Lung Model Market Breakdown, by Application
    • 10.4.4.1 Asia Pacific: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Application
    • 10.4.4.2 Asia Pacific: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by End User
  • 10.4.5 Asia Pacific: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
    • 10.4.5.1 Asia Pacific: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
    • 10.4.5.2 China: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.4.5.2.1 China: In-Vitro Lung Model Market Breakdown, by Type
      • 10.4.5.2.2 China: In-Vitro Lung Model Market Breakdown, by Application
      • 10.4.5.2.3 China: In-Vitro Lung Model Market Breakdown, by End User
    • 10.4.5.3 Japan: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.4.5.3.1 Japan: In-Vitro Lung Model Market Breakdown, by Type
      • 10.4.5.3.2 Japan: In-Vitro Lung Model Market Breakdown, by Application
      • 10.4.5.3.3 Japan: In-Vitro Lung Model Market Breakdown, by End User
    • 10.4.5.4 India: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.4.5.4.1 India: In-Vitro Lung Model Market Breakdown, by Type
      • 10.4.5.4.2 India: In-Vitro Lung Model Market Breakdown, by Application
      • 10.4.5.4.3 India: In-Vitro Lung Model Market Breakdown, by End User
    • 10.4.5.5 South Korea: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.4.5.5.1 South Korea: In-Vitro Lung Model Market Breakdown, by Type
      • 10.4.5.5.2 South Korea: In-Vitro Lung Model Market Breakdown, by Application
      • 10.4.5.5.3 South Korea: In-Vitro Lung Model Market Breakdown, by End User
    • 10.4.5.6 Australia: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.4.5.6.1 Australia: In-Vitro Lung Model Market Breakdown, by Type
      • 10.4.5.6.2 Australia: In-Vitro Lung Model Market Breakdown, by Application
      • 10.4.5.6.3 Australia: In-Vitro Lung Model Market Breakdown, by End User
    • 10.4.5.7 Rest of APAC: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.4.5.7.1 Rest of APAC: In-Vitro Lung Model Market Breakdown, by Type
      • 10.4.5.7.2 Rest of APAC: In-Vitro Lung Model Market Breakdown, by Application
      • 10.4.5.7.3 Rest of APAC: In-Vitro Lung Model Market Breakdown, by End User
• 10.5 Middle East and Africa
  • 10.5.1 Middle East and Africa In-Vitro Lung Model Market Overview
  • 10.5.2 Middle East and Africa: In-Vitro Lung Model Market - Revenue, 2021-2031 (US$ Million)
  • 10.5.3 Middle East and Africa: In-Vitro Lung Model Market Breakdown, by Type
    • 10.5.3.1 Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Type
  • 10.5.4 Middle East and Africa: In-Vitro Lung Model Market Breakdown, by Application
    • 10.5.4.1 Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Application
  • 10.5.5 Middle East and Africa: In-Vitro Lung Model Market Breakdown, by End User
    • 10.5.5.1 Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by End User
  • 10.5.6 Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
    • 10.5.6.1 Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
    • 10.5.6.2 Saudi Arabia: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.5.6.2.1 Saudi Arabia: In-Vitro Lung Model Market Breakdown, by Type
      • 10.5.6.2.2 Saudi Arabia: In-Vitro Lung Model Market Breakdown, by Application
      • 10.5.6.2.3 Saudi Arabia: In-Vitro Lung Model Market Breakdown, by End User
    • 10.5.6.3 South Africa: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.5.6.3.1 South Africa: In-Vitro Lung Model Market Breakdown, by Type
      • 10.5.6.3.2 South Africa: In-Vitro Lung Model Market Breakdown, by Application
      • 10.5.6.3.3 South Africa: In-Vitro Lung Model Market Breakdown, by End User
    • 10.5.6.4 United Arab Emirates: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.5.6.4.1 United Arab Emirates: In-Vitro Lung Model Market Breakdown, by Type
      • 10.5.6.4.2 United Arab Emirates: In-Vitro Lung Model Market Breakdown, by Application
      • 10.5.6.4.3 United Arab Emirates: In-Vitro Lung Model Market Breakdown, by End User
    • 10.5.6.5 Rest of Middle East and Africa: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.5.6.5.1 Rest of Middle East and Africa: In-Vitro Lung Model Market Breakdown, by Type
      • 10.5.6.5.2 Rest of Middle East and Africa: In-Vitro Lung Model Market Breakdown, by Application
      • 10.5.6.5.3 Rest of Middle East and Africa: In-Vitro Lung Model Market Breakdown, by End User
• 10.6 South and Central America
  • 10.6.1 South and Central America In-Vitro Lung Model Market Overview
  • 10.6.2 South and Central America: In-Vitro Lung Model Market - Revenue, 2021-2031 (US$ Million)
  • 10.6.3 South and Central America: In-Vitro Lung Model Market Breakdown, by Type
    • 10.6.3.1 South and Central America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Type
  • 10.6.4 South and Central America: In-Vitro Lung Model Market Breakdown, by Application
    • 10.6.4.1 South and Central America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Application
  • 10.6.5 South and Central America: In-Vitro Lung Model Market Breakdown, by End User
    • 10.6.5.1 South and Central America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by End User
  • 10.6.6 South and Central America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
    • 10.6.6.1 South and Central America: In-Vitro Lung Model Market - Revenue and Forecast Analysis - by Country
    • 10.6.6.2 Brazil: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.6.6.2.1 Brazil: In-Vitro Lung Model Market Breakdown, by Type
      • 10.6.6.2.2 Brazil: In-Vitro Lung Model Market Breakdown, by Application
      • 10.6.6.2.3 Brazil: In-Vitro Lung Model Market Breakdown, by End User
    • 10.6.6.3 Argentina: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.6.6.3.1 Argentina: In-Vitro Lung Model Market Breakdown, by Type
      • 10.6.6.3.2 Argentina: In-Vitro Lung Model Market Breakdown, by Application
      • 10.6.6.3.3 Argentina: In-Vitro Lung Model Market Breakdown, by End User
    • 10.6.6.4 Rest of South and Central America: In-Vitro Lung Model Market - Revenue and Forecast, 2021-2031 (US$ Million)
      • 10.6.6.4.1 Rest of South and Central America: In-Vitro Lung Model Market Breakdown, by Type
      • 10.6.6.4.2 Rest of South and Central America: In-Vitro Lung Model Market Breakdown, by Application
      • 10.6.6.4.3 Rest of South and Central America: In-Vitro Lung Model Market Breakdown, by End User

11. Industry Landscape

• 11.1 Overview
• 11.2 New Product Development
• 11.3 Merger and Acquisition
• 11.4 Partnerships and Collaborations
• 11.5 Other Business Strategies

12. Competitive Landscape

• 12.1 Global Company Market Share Analysis, 2024

13. Company Profiles

• 13.1 MatTek Corp
  • 13.1.1 Key Facts
  • 13.1.2 Business Description
  • 13.1.3 Products and Services
  • 13.1.4 Financial Overview
  • 13.1.5 SWOT Analysis
  • 13.1.6 Key Developments
• 13.2 Lonza Group AG
  • 13.2.1 Key Facts
  • 13.2.2 Business Description
  • 13.2.3 Products and Services
  • 13.2.4 Financial Overview
  • 13.2.5 SWOT Analysis
  • 13.2.6 Key Developments
• 13.3 Emulate, Inc.
  • 13.3.1 Key Facts
  • 13.3.2 Business Description
  • 13.3.3 Products and Services
  • 13.3.4 Financial Overview
  • 13.3.5 SWOT Analysis
  • 13.3.6 Key Developments
• 13.4 CN Bio Innovations Ltd
  • 13.4.1 Key Facts
  • 13.4.2 Business Description
  • 13.4.3 Products and Services
  • 13.4.4 Financial Overview
  • 13.4.5 SWOT Analysis
  • 13.4.6 Key Developments
• 13.5 Merck KGaA
  • 13.5.1 Key Facts
  • 13.5.2 Business Description
  • 13.5.3 Products and Services
  • 13.5.4 Financial Overview
  • 13.5.5 SWOT Analysis
  • 13.5.6 Key Developments
• 13.6 PromoCell GmbH
  • 13.6.1 Key Facts
  • 13.6.2 Business Description
  • 13.6.3 Products and Services
  • 13.6.4 Financial Overview
  • 13.6.5 SWOT Analysis
• 13.7 Charles River Laboratories International Inc
  • 13.7.1 Key Facts
  • 13.7.2 Business Description
  • 13.7.3 Products and Services
  • 13.7.4 Financial Overview
  • 13.7.5 SWOT Analysis
  • 13.7.6 Key Developments
• 13.8 MIMETAS BV
  • 13.8.1 Key Facts
  • 13.8.2 Business Description
  • 13.8.3 Products and Services
  • 13.8.4 Financial Overview
  • 13.8.5 SWOT Analysis
  • 13.8.6 Key Developments
• 13.9 InSphero AG
  • 13.9.1 Key Facts
  • 13.9.2 Business Description
  • 13.9.3 Products and Services
  • 13.9.4 Financial Overview
  • 13.9.5 SWOT Analysis
  • 13.9.6 Key Developments
• 13.10 Organovo Holdings Inc
  • 13.10.1 Key Facts
  • 13.10.2 Business Description
  • 13.10.3 Products and Services
  • 13.10.4 Financial Overview
  • 13.10.5 SWOT Analysis
  • 13.10.6 Key Developments
• 13.11 Draper, Inc.
  • 13.11.1 Key Facts
  • 13.11.2 Business Description
  • 13.11.3 Products and Services
  • 13.11.4 Financial Overview
  • 13.11.5 SWOT Analysis
  • 13.11.6 Key Developments
• 13.12 TissUse GmbH
  • 13.12.1 Key Facts
  • 13.12.2 Business Description
  • 13.12.3 Products and Services
  • 13.12.4 Financial Overview
  • 13.12.5 SWOT Analysis
• 13.13 Epithelix
  • 13.13.1 Key Facts
  • 13.13.2 Business Description
  • 13.13.3 Financial Overview
  • 13.13.4 SWOT Analysis
  • 13.13.5 Key Developments
• 13.14 AlveoliX AG
  • 13.14.1 Key Facts
  • 13.14.2 Business Description
  • 13.14.3 Products and Services
  • 13.14.4 Financial Overview
  • 13.14.5 SWOT Analysis
  • 13.14.6 Key Developments
• 13.15 American Type Culture Collection (ATCC)
  • 13.15.1 Key Facts
  • 13.15.2 Business Description
  • 13.15.3 Products and Services
  • 13.15.4 Financial Overview
  • 13.15.5 SWOT Analysis

14. Appendix

• 14.1 About The Insight Partners
• 14.2 Glossary of Terms